	US 12,070,456 B2
	*Compositions and methods for treating Helicobacter pylori* infection**
Nicola Jones, Whitby (CA); Laura MacDougall, Vaughan (CA); and Mariana Capurro, Toronto (CA)
Assigned to THE HOSPITAL FOR SICK CHILDREN, Toronto (CA)
Filed by The Hospital for Sick Children, Toronto (CA)
Filed on Nov. 1, 2021, as Appl. No. 17/515,706.
Application 17/515,706 is a continuation of application No. 16/091,173, granted, now 11,191,760, previously published as PCT/CA2017/050420, filed on Apr. 6, 2017.
Claims priority of provisional application 62/319,035, filed on Apr. 6, 2016.
Prior Publication US 2022/0096457 A1, Mar. 31, 2022
Int. Cl. A61K 31/445 (2006.01); A61K 31/18 (2006.01); A61K 31/4535 (2006.01); A61K 31/4709 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/4709 (2013.01) [A61K 31/18 (2013.01); A61K 31/4535 (2013.01); A61K 45/06 (2013.01)]

8 Claims

1. A method for treating and/or preventing a disorder associated with disrupted autophagosome maturation in a subject, wherein the disorder is cancer, gastritis, peptic ulcer disease, or an infection resulting from Helicobacter pylori, Salmonella typhimurium, Listeria, Shigella, Legionella pneumophila, Staphylococcus aureus, Mycobacterium tuberculosis, Group A Streptococcus, Epstein-Barr virus (EBV), Hepatitis B or C, human immunodeficiency virus, herpes simplex virus, influenza virus, human respiratory syncytial virus, or cytomegalovirus; the method comprising administering an agent that promotes autophagosome maturation to the subject.